The experimental drug, called AMG510, targets a specific genetic mutation. It had quite a low response rate and shrank the tumor in just one of 12 patients.
On a promising note, the cancer stopped growing in 10 of the patients taking 960mg of AMH510 daily. One patient did have tumor progression, though, according to the Phase I trial data presented in Barcelona at the European Society of Medical Oncology (ESMO) Congress.
Previously, Amgen had reported higher response rates for AMG510 in lung cancer patients.
AMG510 targets a mutated form of the gene known as KRAS. The race is on for Amgen and their competitors, as there is no current drug on the market that does this, and Guggenheim analyst Michael Schmidt recently estimated that drugs targeting KRASG12C could reach annual U.S. sales of $3 billion and $6.4 billion worldwide.
For now, Amgen has not decided whether AMG510 will be placed in a larger Phase 2 colon cancer study, but they do plan on starting a trial this year that tests AMG510 in combination with MEK inhibitors.
As reported by the National Post, “AMG510 is part of a growing trend of precision medicines that target specific gene mutations driving cancer regardless of the organ in which the disease originated.”
Call to Action: To stay informed on gene-targeted trials and developments, sign up for our Newsletter.